MiMedx Group, Inc. (NASDAQ:MDXG) Receives Average Recommendation of “Buy” from Analysts

Shares of MiMedx Group, Inc. (NASDAQ:MDXG) have been assigned a consensus rating of “Buy” from the four ratings firms that are presently covering the company, Marketbeat reports. Four research analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have covered the stock in the last year is $12.25.

A number of research firms have weighed in on MDXG. Lake Street Capital assumed coverage on shares of MiMedx Group in a research note on Thursday, March 7th. They set a “buy” rating and a $12.00 price target on the stock. Mizuho lifted their price target on shares of MiMedx Group from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, March 1st.

MiMedx Group Price Performance

Shares of NASDAQ:MDXG opened at $6.25 on Friday. The business’s 50 day simple moving average is $7.50 and its 200-day simple moving average is $7.56. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.57 and a quick ratio of 3.11. The firm has a market capitalization of $917.77 million, a price-to-earnings ratio of 19.52 and a beta of 1.32. MiMedx Group has a 12 month low of $3.49 and a 12 month high of $9.27.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, February 28th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). MiMedx Group had a net margin of 14.49% and a return on equity of 41.12%. The firm had revenue of $86.83 million during the quarter, compared to analysts’ expectations of $85.58 million. As a group, equities analysts forecast that MiMedx Group will post 0.33 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CAO William Frank Iv Hulse sold 20,381 shares of the stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $7.95, for a total value of $162,028.95. Following the sale, the chief accounting officer now owns 479,959 shares of the company’s stock, valued at approximately $3,815,674.05. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other MiMedx Group news, COO Ricci S. Whitlow sold 15,493 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $8.07, for a total transaction of $125,028.51. Following the sale, the chief operating officer now directly owns 416,321 shares in the company, valued at approximately $3,359,710.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO William Frank Iv Hulse sold 20,381 shares of the stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $7.95, for a total value of $162,028.95. Following the transaction, the chief accounting officer now directly owns 479,959 shares of the company’s stock, valued at $3,815,674.05. The disclosure for this sale can be found here. Insiders sold a total of 51,145 shares of company stock worth $409,378 in the last three months. 19.90% of the stock is owned by insiders.

Institutional Trading of MiMedx Group

A number of large investors have recently added to or reduced their stakes in MDXG. AJOVista LLC bought a new position in shares of MiMedx Group in the fourth quarter valued at $25,000. DekaBank Deutsche Girozentrale acquired a new position in shares of MiMedx Group in the 3rd quarter worth $38,000. Robeco Institutional Asset Management B.V. acquired a new stake in shares of MiMedx Group during the third quarter worth $74,000. M&T Bank Corp purchased a new stake in shares of MiMedx Group during the third quarter valued at $75,000. Finally, E Fund Management Co. Ltd. acquired a new position in shares of MiMedx Group in the 3rd quarter valued at $84,000. 79.15% of the stock is currently owned by institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.